Ken Mills, CEO of RegenxBio, discusses wet-age macular degeneration, the company’s collaboration with AbbVie, and the potential to alter the way patients with this and other eye conditions are treated by using a gene therapy that gets the body to produce a VEGF inhibitor.

Programing the Body to Make Its Own Medicine with Gene Therapy

<p>RARECast is a Global Genes podcast hosted by award-winning journalist Daniel Levine. It focuses on the intersection of rare disease with business, science, and policy. </p>

Business

RARECast is a Global Genes podcast hosted by award-winning journalist Daniel Levine. It focuses on the intersection of rare disease with business, science, and policy.

Share Programing the Body to Make Its Own Medicine with Gene Therapy

Sign up to save your podcasts

Programing the Body to Make Its Own Medicine with Gene Therapy

Programing the Body to Make Its Own Medicine with Gene Therapy